Mon Sep 09 13:38:39 UTC 2024: ## Trump Vows to Rescind Climate Funds in IRA, But Remains Silent on Drug Pricing Provisions
Former President Donald Trump has declared that he will revoke unspent funds allocated to climate provisions within the Inflation Reduction Act (IRA) if elected in November. This pledge, made during a speech to Wall Street and corporate leaders, aims to undo a key piece of President Biden’s signature legislative achievement.
Trump’s statement focuses on rolling back measures aimed at reducing greenhouse gas emissions and air pollution, including funding for “green banks” designed to accelerate the transition to clean energy. He has also expressed his desire to restore presidential authority to withhold congressionally approved spending deemed wasteful.
However, Trump has notably remained silent on another major component of the IRA: the prescription drug pricing provisions. This silence is particularly striking given the popularity of these measures, which grant Medicare the authority to negotiate prices for certain high-cost pharmaceuticals and cap out-of-pocket expenses for Medicare beneficiaries.
While some have speculated that Trump might attempt to repeal these provisions, his past actions suggest otherwise. He has consistently supported Medicare drug price negotiations, even defying Republican orthodoxy by advocating for a “most favored nations” policy that would tie Medicare prices to international benchmarks.
Despite these past pronouncements, Trump’s actual policy implementation has often diverged from his rhetoric. During his first term, he issued multiple executive orders aimed at “improving” the Affordable Care Act (ACA) while simultaneously undermining its core components. Similarly, his approach to the IRA might involve a more nuanced strategy than a full-scale repeal of its drug pricing provisions.
The prospect of a Trump presidency in 2025 could thus lead to a battle over unspent climate funds within the IRA, while the drug pricing provisions remain largely untouched. This potential scenario highlights the complexities and contradictions inherent in Trump’s approach to healthcare policy, which often strays from traditional Republican positions.
First Piper 